Investment
Features
FeesSafety
Academy
More
Pluang+

MGP Ingredients shares plunge 90% since 2022 but now offer strong value with low price multiples and limited downside risk.

Analyst Insights
29 Sep 2026
Seeking Alpha
View Source
Bullish
MGP Ingredients shares plunge 90% since 2022 but now offer strong value with low price multiples and limited downside risk.

MGP Ingredients (MGPI) has seen its share price collapse nearly 90% since 2022 due to a recession and trade challenges in its industry. Despite this, the stock now trades at a deep discount, with price-to-sales at 0.55x and price-to-book at 0.46x, well below peers and historical norms. The forward price-to-earnings ratio is estimated at 6.5x, compared to long-term averages of 20–25x, supported by strong tangible assets and a conservative balance sheet. Analyst Paul Franke upgraded MGPI to a Strong Buy, highlighting limited downside risk and significant upside potential if industry conditions improve.

MGP Ingredients share price performance is the subject here, with context from the Consumer Staples sector on Pluang. Of 51 priced US Consumer Staples stocks, 14 rose and 33 fell today. Notable prices include DNUT at USD 2.92 with a 1-day change of +1.04%, HNST at USD 5.25 with -0.94%, and PEP at USD 127.48 with -0.79% and Pluang order activity showing 7% Sell / 93% Buy. This data is as of Sep 29, 2026 18:22 WIB.

More News

Netflix stock rises after Deutsche Bank upgrades it amid mixed analyst opinions.

Netflix stock rises after Deutsche Bank upgrades it amid mixed analyst opinions.

Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...

Analyst Insights
Bullish
1 hour ago
Cytokinetics insiders, including CEO, sell significant shares amid stock trading below moving averages.

Cytokinetics insiders, including CEO, sell significant shares amid stock trading below moving averages.

Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while th...

Market News
Bearish
1 hour ago
Carnival posts strong quarterly earnings with $1.92B net income amid rising cruise demand

Carnival posts strong quarterly earnings with $1.92B net income amid rising cruise demand

Carnival Corporation reported strong quarterly results with earnings per share of $1.43 and net income of $1.92 billion, surpassing analyst expectations. The company achieved record revenue of $8.44 billion, driven by growing consumer interest in cru...

Company Fundamentals
Bullish
1 hour ago
FactSet expects strong Q3 earnings with $4.35 EPS and $630M revenue, driven by AI demand and cost control.

FactSet expects strong Q3 earnings with $4.35 EPS and $630M revenue, driven by AI demand and cost control.

FactSet is set to report strong Q3 earnings with an expected EPS of $4.35 and revenue around $629.83 million, reflecting a 5.3% increase from last year. The company benefits from high demand for AI-related products, expanded client base, and effectiv...

Company Fundamentals
Bullish
1 hour ago
Jefferies posts strong Q3 with $1.09 EPS and $2.22B revenue, signaling 50% stock upside potential.

Jefferies posts strong Q3 with $1.09 EPS and $2.22B revenue, signaling 50% stock upside potential.

Jefferies Financial Group reported robust Q3 results with earnings per share of $1.09, beating analyst estimates and last year's $1.05. Revenue rose to $2.22 billion, driven by record banking revenue, surpassing expectations. Net earnings increased t...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App